Analyst Price Targets — CLPBY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 25, 2025 1:20 pm | — | Bernstein | $14.45 | $11.07 | TheFly | Coloplast price target raised to $14.45 from $13.50 at Bernstein |
Latest News for CLPBY
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Volatility and Risk Coloplast A/S has a beta
Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs, supports stable, mid-to-high single-digit growth expectations for the long term. Management targets 7–8% organic revenue growth and at least 20% ROIC by FY 2029/30, with current dividend yield above 5% but payout ratio…
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CLPBY.
Senate Trading
No Senate trades found for CLPBY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.